Your position:www.healthoo.com >> EN >> EN >> Formulation >> FDA Issues Drug Statement, Mercks Hypoglycemic Drug Sitagliptin Detected Potential Carcinogen >> article
 
FDA Issues Drug Statement, Mercks Hypoglycemic Drug Sitagliptin Detected Potential Carcinogen
Editor:xuezhe    Clicks:0    Date:2022-8-17 10:04:12
Keyword: FDA
Healthoo Information:
FDA Issues Drug Statement, Mercks Hypoglycemic Drug Sitagliptin Detected Potential Carcinogen
 
 E-mail:xuezhe@healthoo.com
 Tel.:86-10-68032463
  Our services:
 China Im\Ex data service
 Service fees of Chinese Vision
 Our service items
Online information introduction
Monthly information
Relative Information
  • Upadatinibs launch accelerated: Crohns disease has simultaneously subm...
  • FDA Breakthrough Therapy Designation for Topical Vitamin A Derivatives...
  • AstraZenecas Ultomiris Third Indication Approved by US FDA!
  • New Drugs Approved by FDA in February 2022
  • Nature: FDA Approval of New Drugs Sales Forecast in 2021
  • FDA cautions Aurobindo oral solids formulation facility
  • Nhwa received FDA warning Letter for 3 APIs
  • Lihua received import alert from FDA
  • Chuanning 4 APIs passed FDA authentication
  • Modern passed FDA examination
  • Address: Suite 13F,NO2 Building, FuXing International, TianHua North Street, Yizhuang, Daxing District, Beijing, P.R. China
    Tel:+86-10-68032463